Press release 2012-05-31



C-RAD Catalyst[™] Selected as Elekta's Preferred Solution for Free Breathing Gating

Elekta and C-RAD have signed an agreement in which the Catalyst[™] system optical surface tracking has been selected as the Elekta preferred solution for free breathing gating in radiation therapy.

The Catalyst system is based on a new generation of hardware and software platform for high performance optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable clinicians to perform a real-time assessment of patient positioning errors before and during treatment delivery. Interfaces to major vendors ensure a completely integrated workflow.

The Sentinel[™] system was made available to Elekta customers worldwide in 2009. Under this new agreement, Catalyst technology also will be made available via the Elekta sales network.

"Elekta has enjoyed a good working relationship with C-RAD. Together we are demonstrating value for our mutual customers by leveraging Elekta's opens systems philosophy to provide solutions like C-RAD Catalyst and Elekta's Response for free-breathing motion management." says Tim Prosser, Director Oncology Business Line at Elekta.

"This collaboration with Elekta is strategically important," add Erik Hedlund, CEO at C-RAD AB. "We are honored that Elekta selected C-RAD as the preferred supplier for this new and advanced application in respiratory gating. Integrated solutions for auto set up and respiratory gating will be made available to Elekta customers."

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resourceefficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: <u>www.elekta.com</u>.

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 21 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel^{TM,} started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD GmbH in Germany. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.

For more information on C-RAD, please visit <u>www.c-rad.com</u>.

For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46-18-666931, E-mail erik.hedlund@c-rad.se